Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

T-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis

Version 1 : Received: 4 September 2022 / Approved: 7 September 2022 / Online: 7 September 2022 (05:14:06 CEST)

How to cite: Yoshifuji, A.; Toda, M.; Ryuzaki, M.; Oyama, E.; Kikuchi, K.; Kawai, T.; Sakai, K.; Koinuma, M.; Katayama, K.; Uehara, Y.; Ohmagari, N.; Kanno, Y.; Kon, H.; Tanaka, J.; Shinoda, T.; Takano, Y.; Hora, K.; Nakazawa, Y.; Hasegawa, N.; Hanafusa, N.; Hinoshita, F.; Morikane, K.; Wakino, S.; Nakamoto, H.; Takemoto, Y. T-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis. Preprints 2022, 2022090101 (doi: 10.20944/preprints202209.0101.v1). Yoshifuji, A.; Toda, M.; Ryuzaki, M.; Oyama, E.; Kikuchi, K.; Kawai, T.; Sakai, K.; Koinuma, M.; Katayama, K.; Uehara, Y.; Ohmagari, N.; Kanno, Y.; Kon, H.; Tanaka, J.; Shinoda, T.; Takano, Y.; Hora, K.; Nakazawa, Y.; Hasegawa, N.; Hanafusa, N.; Hinoshita, F.; Morikane, K.; Wakino, S.; Nakamoto, H.; Takemoto, Y. T-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis. Preprints 2022, 2022090101 (doi: 10.20944/preprints202209.0101.v1).

Abstract

Most studies on vaccines of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused on antibody, but cellular immunities are also critical. We aimed to evaluate the immune reactions of hemodialysis (HD) patients after the administration of the booster dose from the perspective of both humoral and cellular immunities. Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (control group) receiving three doses of BNT162b2 vaccine were measured for anti-SARS-CoV-2 immunoglobulin (IgG) and T-SPOTⓇ.COVID test (T-SPOT) before, 3 weeks, and 3 months after the booster dose. The HD group had significantly higher SARS-CoV-2 IgG levels 3 weeks and 3 months after the booster dose than the control group, although both groups had no difference in SARS-CoV-2 IgG levels before the booster dose. Moreover, the HD group had significantly higher T-SPOT levels before and 3 weeks after the booster dose than the control group, but the difference was not significantly different 3 months after the booster dose. Furthermore, the incidence rates of local and systemic adverse reactions were significantly higher in the HD group than in the control group. HD patients obtained higher SARS-CoV-2 IgG levels and SARS-COV-2-specific T-cell responses after the booster dose than control.

Keywords

COVID-19; hemodialysis; vaccination; cellular immunity; humoral immunity; adverse reactions

Subject

MEDICINE & PHARMACOLOGY, General Medical Research

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.